Peter Attia MD373 – Thyroid function & hypothyroidism: how new approaches are transforming care
CHAPTERS
- 0:01 – 9:02
Thyroid basics: iodine, T4 storage, and active T3
Antonio Bianco describes his research on how thyroid hormone regulates gene expression, and Peter Attia frames the thyroid's role. Bianco explains how the gland takes up iodine, stores T4, and how removing one iodine yields receptor-binding T3 with a much shorter half-life.
- •Bianco's lab studies what T3 does in tissues and how it affects chromatin folding and gene expression
- •The thyroid traps dietary iodine and stores mostly inactive T4
- •Receptors bind T3 with high affinity, not T4, because of the shape of the binding pocket
- •The system evolved to preserve iodine, which is recycled
- •T4 half-life is about 8 days versus about 12 hours for T3
- 9:02 – 18:07
Reverse T3 and what fasting does to thyroid hormones
Attia asks about reverse T3 and shares his own lab numbers before and after extended fasts. Bianco explains how the hypothalamus, deiodinase shifts and reduced liver D1 activity lower T3 and raise reverse T3 to conserve energy.
- •Removing an inner-ring iodine makes reverse T3, which is essentially inactive
- •Fasting lowers insulin and leptin, and the hypothalamus slows energy expenditure
- •T4 is shunted toward reverse T3, and D1 clearance of reverse T3 falls in the liver
- •The T3 to reverse T3 ratio is a useful surrogate for deiodinase activity, with caveats
- 18:07 – 22:59
D1, D2, and D3: how deiodinases activate and inactivate hormone
Bianco describes the three deiodinases: D2 as the efficient activator producing most extrapituitary T3, D3 as the inactivator, and D1 as a weaker enzyme. They clarify that reverse T3 and T2 are both dead end products and that the path is one-way.
- •D2 has far higher affinity for T4 than D1 and makes about 80% of T3 made outside the thyroid
- •D3 inactivates T3 into T2 and turns T4 into reverse T3
- •Reverse T3 does not bind the receptor, and T2 is too short-lived to be useful to measure
- •Iodine is recycled and there is no path from reverse T3 back to T3
- 22:59 – 34:12
The hypothalamic-pituitary axis and tissue-level T3 control
They go through TRH, TSH, and the feedback loop, stressing that symptoms come from thyroid hormone levels rather than TSH. Bianco explains that blood levels are very stable while tissue T3 can swing tenfold through local D2, citing his brown fat work and the hypothalamus's access to blood signals.
- •TRH from the hypothalamus drives pituitary TSH, which stimulates the thyroid; TSH itself causes no symptoms
- •Thyroid hormone levels are unusually stable compared with insulin
- •Cold exposure raised brown fat T3 about tenfold with no change in blood
- •Most brain T3 is produced locally by D2
- •The medial basal hypothalamus sits outside the blood-brain barrier, and D2 there allows T4 to trigger feedback
- 34:12 – 45:41
Why physiology matters and how to read thyroid tests
Attia and Bianco argue that understanding physiology is needed to judge treatments, and Bianco says the school of thought against measuring T3 makes no sense. They then cover total versus free hormone, binding proteins, and why T3 and reverse T3 immunoassays are unreliable while free T4 is good.
- •Bianco says many people discussing treatment have an incomplete grasp of thyroid physiology
- •About 99.5% of T3 and T4 is protein-bound, and only the free fraction enters tissues
- •Estrogen and pregnancy raise binding proteins and total T4 without changing free T4
- •Free T4 and TSH immunoassays are reliable, but T3 and reverse T3 assays are variable and mass spec is needed
- •Large labs generally do not offer routine mass spec for T3
- 45:41 – 48:17
Genetic and sex differences in thyroid regulation
Attia asks how much genetics and sex influence thyroid hormone levels. Bianco says there is some genetic influence and a broader TSH range in women, but he doesn't think either is clinically relevant at this point.
- •Dutch studies suggest some genetic influence on thyroid function
- •Genetics might matter when deciding a target TSH but the effect is small
- •Women have a broader TSH range than men
- •Neither difference is judged clinically relevant
- 48:17 – 1:00:10
Hyperthyroidism: Graves' disease, nodules, and treatment options
They compare how common hypo- and hyperthyroidism are, then Bianco covers the causes of hyperthyroidism. He describes Graves' disease symptoms, diagnosis, and the three treatment options, noting the shift away from radioactive iodine because of cancer concerns.
- •About 20 million Americans have hypothyroidism, while hyperthyroidism is far rarer
- •Graves' disease involves a TSH-receptor-stimulating antibody; TSH is suppressed and free T4 and T3 are high
- •Treatments are antithyroid drugs (30-40% remission), surgery, or radioactive iodine
- •Radioactive iodine is associated with increased cancer incidence, so use has declined
- •Hot nodules do not remit, and Bianco favors surgery given today's skilled surgeons
- 1:00:10 – 1:12:13
Hypothyroidism and Hashimoto's: how it is diagnosed and what antibodies mean
Attia opens by asking how hypothyroidism is usually discovered. Bianco explains that most cases are now found by routine TSH screening and that Hashimoto's is the most common cause. The discussion covers TPO antibodies in pregnancy, other autoimmune implications, and what led Bianco to focus on patients who stay symptomatic.
- •Diagnosis today usually starts with an elevated TSH on routine labs
- •Hashimoto's involves immune destruction and shrinkage of the thyroid
- •Replacing hormone alone ignores that TPO positivity is linked to miscarriage and prematurity even with normal thyroid function
- •Bianco recounts seeing patients who lost jobs to brain fog after thyroid removal despite normal labs
- •Selenium, vitamin D, and antioxidants may prolong the honeymoon period but are not standard care
- 1:12:13 – 1:20:57
Diagnostic criteria, antibody patterns, and non-autoimmune causes
Bianco explains that diagnosis rests on TSH and free T4, not antibodies, and how a positive TPO with normal free T4 is handled. About 40% of cases lack TPO antibodies, with causes including surgery, radioactive iodine, congenital disease, and unnamed autoimmune forms.
- •Primary hypothyroidism requires high TSH together with low free T4
- •A positive TPO with normal free T4 is watched and may be rechecked rather than treated
- •About 60% of patients have positive TPO antibodies
- •Non-TPO causes include surgery, radioactive iodine, congenital hypothyroidism, and other autoimmune forms
- •Bianco is unaware of trials using steroids to halt Hashimoto's
- 1:20:57 – 1:34:47
Levothyroxine, T3, and desiccated thyroid: the treatment debate
Attia and Bianco review FDA-approved therapies, noting levothyroxine is standard and T3 alone is not recommended. They make the case for and against desiccated thyroid and discuss how both it and levothyroxine were grandfathered without clinical trials.
- •Levothyroxine is the standard of care, and its long half-life makes dosing easy
- •T3 monotherapy is not recommended because of its short half-life
- •Desiccated thyroid extract is pig thyroid powder containing T4 and T3 in roughly a 4:1 ratio
- •Safety concerns about T3 spikes lack evidence, and USP standardized potency testing in 1985
- •Neither desiccated thyroid nor levothyroxine had clinical trials requested for approval
- 1:34:47 – 1:43:19
Mortality signals and incomplete restoration of euthyroidism
Bianco reports a retrospective study showing 2.5 times higher mortality in treated hypothyroid patients versus healthy controls, and 30% lower mortality with combination therapy than with levothyroxine. They discuss confounding, the liver staying hypothyroid, and cholesterol and statin use.
- •Treated hypothyroid patients had 2.5 times the mortality of controls in a 1.1 million patient comparison
- •Bianco doesn't think levothyroxine does harm but that it restores euthyroidism incompletely
- •Cholesterol often stays elevated after TSH normalizes, and statins are the top co-medication
- •Combination therapy was associated with 30% lower mortality than levothyroxine alone
- •Attia raises confounding, and Bianco says they matched for prior admissions, comorbidities, BMI, sex, and age
- 1:43:19 – 1:52:11
Functional medicine, symptoms, and diagnosing secondary hypothyroidism
Attia asks why some functional medicine practitioners find hypothyroidism everywhere. Bianco says diagnosis must rely on TSH and free T4 because symptoms and low temperature are non-specific, and secondary hypothyroidism is rare and still requires low free T4.
- •T3 has no role in diagnosing hypothyroidism because it stays normal until late
- •Secondary hypothyroidism is under 1% of cases and requires a below-normal free T4
- •Symptoms like fatigue, weight gain, and hair loss overlap with menopause, anemia, and other conditions
- •Low temperature can accompany hypothyroidism but does not prove it
- •Antibodies are not needed for the diagnosis
- 1:52:11 – 2:08:05
Compounded controlled-release T3, brand vs generic, and Bianco's treatment approach
Bianco says there is no published evidence that compounded controlled-release T3 is actually slow-release and explains why dosing tiny amounts is hard. They cover his approach of levothyroxine first with closer cardiometabolic monitoring, synthetic combination therapy for residual symptoms, and why brand versus generic levothyroxine doesn't matter.
- •No paper shows a compounded product with a slow-release profile
- •Bianco starts with levothyroxine, treats hypothyroidism as a cardiometabolic risk factor, and adds T3 after excluding other causes
- •He prefers synthetic combination therapy for its adjustable ratio, but considers desiccated thyroid fine
- •Studies show brand and generic levothyroxine are the same, and the FDA tightened potency to plus or minus 5%
- •Guideline goal is normal TSH and free T4, but Bianco argues persistent symptoms mean therapy is incomplete
- 2:08:05 – 2:18:44
Case studies: very high TSH and an extreme TSH response
Attia presents two patients, one with persistently elevated TSH despite treatment and one whose TSH swings from near zero to elevated with small dose changes. Bianco suggests assay interference from rodent antibodies or aggregated TSH, and says to rely on free T4 when TSH is unreliable.
- •First case: a man with TSH 74.7 and free T4 low normal whose TSH stayed elevated while symptomatic on therapy
- •Bianco's first suspicion is assay interference from antibodies against rodent proteins
- •Aggregated TSH or long-standing hypothyroidism could also be factors
- •For the second case with a very sensitive TSH response, there is no known syndrome to explain it
- •In such cases Bianco would follow free T4 instead of TSH, as in pregnancy with hyperthyroidism
- 2:18:44 – 2:27:54
High-dose iodine, sex differences, and subclinical hypothyroidism
Attia asks about high-dose iodine supplements, and Bianco says excess iodine raises autoimmune thyroid disease risk. They discuss the roughly 10 to 1 female predominance of hypothyroidism, then a case of subclinical hypothyroidism and age-adjusted TSH ranges.
- •Excess iodine can trigger autoimmune hypothyroidism and iodine-induced hyperthyroidism with silent nodules
- •Women have about ten times the incidence of hypothyroidism, with no consistent explanation
- •A 40-year-old with TSH 8-9 and normal free T4 is subclinical, and Bianco would work up family history, ultrasound, and TPO
- •Bianco would favor treatment in the younger patient, though Attia's patient felt worse on Synthroid
- •After age 50 the TSH upper limit rises about one point per decade, so mildly elevated TSH in older adults should not be treated
- 2:27:54 – 2:34:14
Future of treatment: mass spec T3, slow-release T3, and Bianco's book
Attia asks what should be known within a decade. Bianco calls for better treatments, routine mass spec for T3, and a pharmaceutical slow-release T3, describing a polymer approach in the US and sulfated T3 in Europe, then they discuss his book and closing remarks.
- •Bianco says treatment must move beyond normalizing TSH
- •Mass spec for T3 is mandatory in his view
- •A US company's polymer T3 completed phase one and is working with the FDA on a short phase two
- •An Italian group is studying sulfated T3, which the liver converts steadily to T3
- •His book Rethinking Hypothyroidism aims at the middle ground between TSH-only and everyone-has-hypothyroidism views
